Randomized phase III trial of erlotinib versus docetaxel for patients with previously treated advanced non-small cell lung cancer
- Conditions
- Previously treated non-small cell lung cancer
- Registration Number
- JPRN-UMIN000002314
- Lead Sponsor
- ational Hospital Organization Headquarters Center for Support and Education of Clinical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Not provided
1)History of obvious distributed interstitial pneumonia or pulmonary fibrosis detected by chest CT (Patients with radiation peumonitis limited to radiation field are eligible) 2)History of obvious drug induced interstitial pneumonia or pneumoconiosis 3)History of symptomatic brain metastases. Patients with brain metastases are eligible, if thier brain metastases are controlled by radiotherapy or drug therapy. 5)History of severe drug allergy 6)History of poorly controlled pleural effusion, pericardial effusion or ascites necessitating drainage 7)History of active infection or other serious disease condition (poorly controlled diabetes mellitus, poorly controlled cardiac disease, GI bleeding, cirrhosis, ileus, persistant watery diarrhea, etc) 8)History of active double cancer 9)History of active psychological disease. 10) History of pregnancy or lactation 11) Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method